Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Anixa Biosciences (NASDAQ:ANIX) issued its earnings results on Friday. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01, Zacks reports.

Anixa Biosciences Price Performance

Shares of ANIX opened at $3.21 on Monday. The firm has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $3.00. The stock has a market cap of $102.75 million, a price-to-earnings ratio of -8.68 and a beta of 0.86. Anixa Biosciences has a 1-year low of $2.14 and a 1-year high of $5.13.

Analysts Set New Price Targets

A number of brokerages have commented on ANIX. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Wednesday, July 24th. EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Insider Transactions at Anixa Biosciences

In other news, Director Lewis H. Titterton, Jr. purchased 21,646 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were bought at an average cost of $3.06 per share, with a total value of $66,236.76. Following the purchase, the director now directly owns 890,754 shares of the company’s stock, valued at $2,725,707.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased a total of 27,051 shares of company stock valued at $82,780 over the last three months. 22.60% of the stock is currently owned by insiders.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.